Everpar Advisors LLC Buys New Shares in Gilead Sciences, Inc. $GILD

Key Points

• Everpar Advisors LLC has acquired a new stake in Gilead Sciences, purchasing 3,012 shares valued at approximately $334,000.
• Several analysts have recently upgraded Gilead Sciences' stock ratings, with target prices ranging from $127.00 to $145.00, indicating positive outlooks for the company's performance.
• Gilead Sciences has announced a quarterly dividend of $0.79 per share, representing a 2.9% dividend yield, with the payout scheduled for September 29th.

Everpar Advisors LLC purchased a new position in shares of Gilead Sciences, Inc. (NASDAQ:GILD - Free Report) in the 2nd quarter, according to the company in its most recent filing with the SEC. The institutional investor purchased 3,012 shares of the biopharmaceutical company's stock, valued at approximately $334,000.

Several other large investors have also modified their holdings of GILD. Brighton Jones LLC grew its position in Gilead Sciences by 20.6% in the fourth quarter. Brighton Jones LLC now owns 14,359 shares of the biopharmaceutical company's stock valued at $1,326,000 after acquiring an additional 2,450 shares during the period. Bison Wealth LLC bought a new stake in Gilead Sciences during the 4th quarter worth about $215,000. Zurich Insurance Group Ltd FI grew its position in shares of Gilead Sciences by 232.1% in the 4th quarter. Zurich Insurance Group Ltd FI now owns 908,894 shares of the biopharmaceutical company's stock valued at $83,955,000 after acquiring an additional 635,209 shares during the period. Waverly Advisors LLC boosted its position in Gilead Sciences by 8.6% during the fourth quarter. Waverly Advisors LLC now owns 29,181 shares of the biopharmaceutical company's stock worth $2,695,000 after purchasing an additional 2,320 shares during the period. Finally, UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC lifted its holdings in shares of Gilead Sciences by 15.1% during the fourth quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 12,234,672 shares of the biopharmaceutical company's stock worth $1,130,117,000 after buying an additional 1,605,730 shares in the last quarter. 83.67% of the stock is owned by institutional investors.

Insider Activity

In other Gilead Sciences news, insider Johanna Mercier sold 3,000 shares of the firm's stock in a transaction dated Monday, September 15th. The stock was sold at an average price of $113.57, for a total value of $340,710.00. Following the completion of the sale, the insider owned 113,193 shares of the company's stock, valued at approximately $12,855,329.01. This trade represents a 2.58% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, CEO Daniel Patrick O'day sold 10,000 shares of Gilead Sciences stock in a transaction on Thursday, August 28th. The stock was sold at an average price of $113.63, for a total transaction of $1,136,300.00. Following the sale, the chief executive officer owned 595,725 shares of the company's stock, valued at $67,692,231.75. The trade was a 1.65% decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last quarter, insiders sold 82,000 shares of company stock worth $9,390,030. Insiders own 0.27% of the company's stock.

Wall Street Analyst Weigh In

A number of equities research analysts have recently weighed in on GILD shares. Dbs Bank upgraded shares of Gilead Sciences to a "moderate buy" rating in a research note on Friday, September 5th. Royal Bank Of Canada raised their price objective on shares of Gilead Sciences from $96.00 to $98.00 and gave the company a "sector perform" rating in a research note on Friday, August 8th. UBS Group increased their target price on shares of Gilead Sciences from $108.00 to $112.00 and gave the company a "neutral" rating in a report on Friday, August 8th. Rothschild & Co Redburn upped their price objective on shares of Gilead Sciences from $136.00 to $143.00 and gave the company a "buy" rating in a report on Friday, September 12th. Finally, Daiwa Capital Markets upgraded Gilead Sciences from a "neutral" rating to an "outperform" rating and set a $128.00 price target on the stock in a research report on Tuesday, August 19th. Three equities research analysts have rated the stock with a Strong Buy rating, nineteen have given a Buy rating and six have issued a Hold rating to the stock. Based on data from MarketBeat, the company currently has a consensus rating of "Moderate Buy" and an average price target of $117.17.

Gilead Sciences Stock Up 0.4%

Shares of Gilead Sciences stock traded up $0.47 during trading on Friday, hitting $114.09. 12,580,487 shares of the stock traded hands, compared to its average volume of 5,841,828. The company has a current ratio of 1.32, a quick ratio of 1.15 and a debt-to-equity ratio of 1.13. The firm has a market cap of $141.56 billion, a P/E ratio of 22.73, a price-to-earnings-growth ratio of 0.77 and a beta of 0.36. The stock's fifty day simple moving average is $114.10 and its 200 day simple moving average is $110.06. Gilead Sciences, Inc. has a 52-week low of $81.83 and a 52-week high of $121.83.

Gilead Sciences (NASDAQ:GILD - Get Free Report) last issued its quarterly earnings data on Thursday, August 7th. The biopharmaceutical company reported $2.01 earnings per share (EPS) for the quarter, beating the consensus estimate of $1.96 by $0.05. The company had revenue of $7.08 billion for the quarter, compared to analyst estimates of $6.95 billion. Gilead Sciences had a net margin of 21.86% and a return on equity of 50.99%. Gilead Sciences's revenue was up 1.4% compared to the same quarter last year. During the same period last year, the company posted $2.01 earnings per share. Gilead Sciences has set its FY 2025 guidance at 7.950-8.250 EPS. On average, equities analysts predict that Gilead Sciences, Inc. will post 7.95 earnings per share for the current fiscal year.

Gilead Sciences Dividend Announcement

The company also recently announced a quarterly dividend, which will be paid on Monday, September 29th. Shareholders of record on Monday, September 15th will be paid a $0.79 dividend. This represents a $3.16 annualized dividend and a yield of 2.8%. The ex-dividend date is Monday, September 15th. Gilead Sciences's dividend payout ratio (DPR) is 62.95%.

Gilead Sciences Company Profile

Gilead Sciences, Inc, a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, Sunlencs, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of COVID-19; and Epclusa, Harvoni, Vemlidy, and Viread for the treatment of viral hepatitis.